Testicular Cancer
Also known as: Testis, Testes, Testicular, Testicle
Methodology & AI Transparency ⓘ
Testicular Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is testicular cancer? Testicular cancer is a cancer that develops in the tissues of one or both testicles.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C62.90 for Testicular Cancer clinical workups.
- 3 Typical cash cost range: Workup highlights for Testicular Cancer (C62.90): radiation) paired with in Testicular Cancer (C62.90: proactive supportive symptom).
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Testicular Cancer (C62.90): Complete Blood Count in Testicular Cancer (C62.90: (ANC, Hemoglobin, Platelets)) & Comprehensive Metabolic & in Testicular Cancer (C62.90: Organ Function Panel) (Preserved renal/hepatic clearance (C62.90)).
Ask our AI Specialists anything about Testicular Cancer
What Is Testicular Cancer?
What is testicular cancer? Testicular cancer is a cancer that develops in the tissues of one or both testicles. The testicles, or testes, are part of the male reproductive system. They make male hormones and sperm. They are two egg-shaped glands inside the scrotum, a sac of loose skin that lies below the penis. You can get cancer in one or both testicles. Who is most likely to develop testicular cancer? Testicular cancer is very rare. You can get it at any age, but it is most common in men between the ages of 20 and 39.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Testicular Cancer (C62.90, Cancer & Oncology) reflects tumor-suppressor loss enabling in Testicular Cancer (C62.90: clonal proliferation). Cross-referenced with NIH MeSH (Testicular Neoplasms), longitudinal control is benchmarked via Complete Blood Count in Testicular Cancer (C62.90: (ANC, Hemoglobin, Platelets)).
Common Symptoms & Clinical Signs
- • Have had abnormal testicle development
- • Have had an undescended testicle, a condition in which one or both testicles fail to move into the scrotum before birth
- • Presentation of Testicular Cancer (C62.90): unintended weight loss [Testicular Cancer C62.90]
- • Secondary Testicular Cancer clinical sign: unexplained bleeding, chronic in Testicular Cancer (C62.90: hoarseness/cough, or progressive)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Testicular Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C62.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Testicular Cancer (C62.90: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C62.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Testicular Cancer (C62.90: Organ Function Panel) | Preserved renal/hepatic clearance (C62.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Testicular Cancer (C62.90: Genomic Staging) | Guideline-concordant surveillance (C62.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Testicular Cancer
Treatment selection for Testicular Cancer depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Testicular Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Glucagon-like peptide 1 receptor agonists on testicular: What a 680-Participant Study Found Our systematic review and meta-analysis suggest a possible role for GLP-1RAs in the therapy of functional hypogonadism related to overweight and obesity, while also promoting weight loss. Andrology • 2025-11-15 • Meta-Analysis | N = 680 | 91/100 | PMID 40105090 ↗ |
| New Insights on Transcriptomic profiling of adjuvant colorectal cancer identifies three key: What a 1,062-Participant Study Found This work furthers our understanding of the underlying biology that propagates stage II/III CRC disease progression and provides scientific rationale for future high-risk stratification and targeted treatment evaluation in... PloS one • 2021-01-15 • Phase III Randomized Trial | N = 1,062 | 90/100 | PMID 34972191 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of short-term oral phytoestrogen supplementation on the Phytoestrogen treatment interferes with HPT axis in CaP patients by inducing testicular resistance to LH and compensated hypogonadism. The Prostate • 2006-07-01 • Randomized Controlled Trial | N = 40 | 88/100 | PMID 16637075 ↗ |
| New Insights on Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal: What a 266-Participant Study Found In this randomized clinical trial, IC did not improve 3-year PFS for LA-NPC patients and increased hematological toxicity. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2026-10-15 • Phase III Randomized Trial | N = 266 | 87/100 | PMID 42604670 ↗ |
| What the Latest Evidence Really Says About Testosterone deficiency in testicular cancer survivors - a systematic review and Strong evidence exists that standard CT, non-conventional therapy and infradiaphragmatic RT are associated with an increased risk of TD in TGCC-patients when compared with orchiectomy alone. Andrology • 2016-05-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 27009402 ↗ |
Testicular Cancer Patient Community & “People Like Me” Threads
Filter Testicular Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.